⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842561 | 1.00 | — | — | |
| SCHEMBL18305943 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL15968265 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20531669 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL15152602 | 0.97 | — | — | |
| SCHEMBL8922980 | 0.80 | — | — | |
| SCHEMBL204338 | 0.80 | — | — | |
| SCHEMBL204337 | 0.80 | — | — | |
| SCHEMBL23331578 | 0.79 | — | — | |
| SCHEMBL1408402 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686182-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-07-29 | — | — | EP | claimed |
| US-20200207782-A1 | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2020-07-02 | — | — | US | claimed |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024032747-A1 | TRICYCLIC COMPOUNDS AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-20230365587-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-16 | — | — | US | disclosed |
| EP-4225762-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230159441-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | 3I, LP | 2023-05-25 | — | — | US | disclosed |
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20230147458-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-05-11 | — | — | US | disclosed |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-11-07 | — | — | US | disclosed |
| EP-2657227-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2013-10-17 | — | — | US | disclosed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |